MXPA00008888A - Novel compositions of eprosartan - Google Patents

Abstract

This invention relates to a novel composition comprising eprosartan, or a salt, solvate, or hydrate thereof, in particulate form, a process for its production and methods of using the composition to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.

Description

NOVELTY COMPOSITIONS OF EPROSARTAN FIELD OF THE INVENTION This invention relates to novel acid compositions (E) -a- [2-n-butyl-1 - [(4-carboxyphenyl) methyl] -1H-imidazol-5-yl] methylene-2-thiophenepropionic [eprosartan] or its methanesulfonate salt [eprosartan mesylate] , and to the use of said compositions in therapy to block angiotensin II (All) receptors and in the treatment of hypertension, congestive heart failure and renal failure.

BACKGROUND OF THE INVENTION * The compound, (E) -a- [2-n-butyl-1 - [(4-carboxyphenyl) methyl] -1H-imidazol-5-yl] methylene-2-thiophenepropionic acid is known by the name "eprosartan" and it is the object of the US patent No. 5,185,351 (the 351 patent), issued February 9, 1993. This patent describes a process for making the anhydrous form of (E) - - [2-n-butyl-1 - [(4-carboxyphenyl) methyl] acid ] -1 H-imidazol-5-yl] methylene-2-thiophenepropionic acid and its methanesulfonate salt. In addition, the '351 patent discloses conventional techniques for formulating (E) -a- [2-n-butyl-1 - [(4-carboxyphenyl) methyl] -1 H -imidazoI-5-yl] methylene-2-thiophenepropionic acid. co. Eprosartan mesylate has the following structure: It is claimed that this compound has utility to block angiotensin II receptors and is useful in the treatment of hypertension, congestive heart failure and renal failure. It is known that pharmaceutically active compounds can be subjected to spraying procedures to obtain a suitable particle size for tabletting and for other types of formulations. Spraying with air jet and spraying with fluid energy (micronization) have been favored due to the reduced risk of introducing contamination from the mill materials. However, wet spraying processes have been proposed for the preparation of finally divided particles for pharmaceutical use, for example, see U.S. Pat. No. 5,145,684. This patent discloses a wet spraying process for producing particles of a crystalline drug substance having a surface modifier absorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm . It is noted that this particulate composition as a stable suspension provides improved bioavailability for poorly water soluble compounds. In accordance with the present invention, it has been found that eprosartan, or its salts, solvates or hydrates can be formulated in novel compositions having an increased therapeutic activity of 2 to 5 times that of the immediate release tablet formulations of the same compound conventionally prepared. These novel compositions have increased bioavailability.

BRIEF DESCRIPTION OF THE INVENTION The present invention is based on the discovery that (E) -a- [2-n-butyl-1 - [(4-carboxyphenyl) methyl] -1H-imidazol-5-yl] methylene-2-thiophenpropionic acid , or their salt forms, such as mesylate, have increased bioavailability in certain compositions of controlled particle size. The anhydrous eprosartan, or its salts, its solvates or hydrates, can be used in the compositions of the present invention. The present invention provides novel compositions comprising eprosartan, or a salt, solvate or hydrate thereof, in the form of particles, said composition having a particle size distribution such that the average value of the average volume diameter is within the scale from 450 to 700 nm.

This invention also provides a method or a method for producing said compositions in a reproducible manner for the treatment of diseases in which blocking of angiotensin II receptors is indicated, for example, in the treatment of hypertension, congestive heart failure and insufficiency. renal.

DESCRIPTION OF THE INVENTION In accordance with the present invention, compositions comprising eprosartan, or its salt, are provided in the form of particles, such as immediate release (IR) capsules and immediate release / delayed release / modified release tablets. The compositions are prepared using a method that includes a wet spray step to produce a particle size distribution of eprosartan, or its salt, with an average volume diameter on the 450-700 nm scale.

The particulate suspension produced in this manner is spray dried using a spray drier or granulated using a fluid bed granulator. The compositions are prepared by mixing and, thus, are suitably adapted for oral, parenteral or pulmonary administration. The compositions may be in the form of tablets, capsules, reconstitutable powders or suppositories. Orally administrable compositions are preferred, in particular oral compositions configured, since they are more convenient for mass therapy.

To aid in further processing, ie the preparation of pharmaceutical compositions for therapeutic use such as capsules and tablets, the wet spraying of eprosartan, or its salt, takes place in an aqueous medium containing one or more water-soluble and pharmaceutically acceptable carriers. suitable for spray drying. The aqueous suspension may optionally contain a surfactant to maintain the particles in suspension until the administration of the pharmaceutical formulation to a patient. The pharmaceutically acceptable excipients most suitable for spray drying are water-soluble hydroxypropylmethylcellulose, a binder, mannitol, but other binders such as polyvinylpyrrolidone (PVP), hydroxypropylcellulose (HPC) and methylcellulose, or other carbohydrates, such as sucrose, can also be used as a carrier. , sorbitol, lactose, lactitol and xylitol and starch. In the aqueous medium that will be subjected to spraying, eprosartan, or its salt, may be present in an amount of 10 to about 40% w / w. In practice, a drug load of 20% w / w provides a compromise effect between the desire for high emission and short spraying times. The amount of the primary vehicle, such as hydroxypropylmethylcellulose (HPMC), can vary from about 2 to about 20% w / w of the composition that will be sprayed. The secondary vehicle, such as mannitol, can also be added to the suspension before spraying or dissolved in the spray suspension before spray drying. Preferably, the total amount of the soluble vehicle does not exceed 100% by weight of eprosartan, or its salt, which will be processed. For an eprosartan loading of about 20% w / w, it has been found that an amount of HPMC of about 4 to 12% w / w is effective, and an amount of about 6% w / w is preferred. The amount of surfactant / slider, if present, may vary from about 0.1 to about 0.4% w / w of the aqueous medium. Preferably, it is present at about 1% by weight of eprosartan, or its salt. Suitable surfactants are sodium laurelsulfate and tween 80, although suitable glidants are silicon dioxide and talc. The compositions of this invention are most suitably prepared by wet spraying eprosartan, or its salt, preferably using a spherical mill such as a Premier HML Laboratory Supermill, manufactured by Premier Mili Corporation, Reading, PA. The spray medium consists of zirconium oxide spheres. Spherical mills manufactured by others such as Dena Mili by Dena Systems BK Ltd., Bamsley, England, can be used to wet-spray eprosartan, or its salt. The particle size distributions of the formulations for suspension were determined using a Malvern laser diffraction unit, Master Sizer S model S4700, from Malvern Instruments Ltd., Malvern, England. Any other particle size configurator can be used by laser diffraction of sufficient sensitivity and resolution for nanoparticles. The eprosartan particles, or their salt, are typically present with not less than 50% of the particles having an average volume diameter of 1000 nm or less. In a preferred embodiment of the invention, the average volume diameter is in the range of 450 to 700 nm. In this average scale, effective compositions are obtained when 90% of the particles have an averaged volume diameter of 1200 nm or less. Using the spray spheres and the aqueous vehicle system described above, a composition having the preferred particle size distribution can be obtained in a surprisingly rapid manner, for example, after spraying 2.5 kg of slurry in the mill for one hour. The increase in the spray time, for example, by five times, makes it possible for the larger particles to be reduced so that at least 90% of the particles have an average volume diameter of less than 1000 nm. However, the effect on the average value is marginal, so that longer spraying times are not cost effective. Spray drying / fluid bed granulation of spray compositions is most suitably carried out using a spray dryer such as Yamato GA-32 Spay Dryer [Yamato Scientific America Inc., Orangeburg, NY], or a bed granulator fluid, such as a Glatt fluid bed granulator.

Tablets and capsules for oral administration are normally presented in a unit dose, and contain conventional excipients such as binding agents, fillers and diluents (tableting or compression aids), lubricants, disintegrants, colorants, flavors and wetting agents. The tablets may be coated according to techniques well known in the art. Suitable binders include polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose and pregelatinized starch (Starch 1551). Suitable fillers include microcrystalline cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include disintegrants such as interlaced polyvinylpyrrolidone (Crospovidone XL), sodium starch glycolate (Explotab) and croscarmellose sodium (Ac-Di-Sol).

Suitable lubricants include stearic acid and magnesium stearate. These solid oral compositions can be prepared by conventional methods of mixing, filling, tapping or the like. Repeated mixing operations can be used to distribute the active ingredient throughout those compositions using large amounts of fillers. Such operations are, of course, well known in the art. Oral formulations also include conventional controlled release formulations, such as tablets or pellets, spheres or granules, which have a prolonged release or an enteric coating, or otherwise modified to control the release of the active compound, for example, by inclusion of gel-forming polymers or matrix-forming waxes. Advantageously, a surfactant or wetting agent may be included in the composition to facilitate uniform distribution of the compound of the invention. In this manner, the present invention provides a novel composition comprising eprosartan, or its salts, solvates or hydrates. The composition is adapted for oral administration. The composition is presented as a unit dose. Said composition is preferably taken one to two times a day. Preferred unit dosage forms include tablets or capsules. The compositions of this invention can be formulated by conventional mixing methods such as blending, filling and compression. Suitable pharmaceutically acceptable carriers for use in this invention include diluents, fillers, binders and disintegrants. Eprosartan, or its salts, solvates or hydrates, may be coadministered with other pharmaceutically active compounds, for example, in physical combination or by sequential administration. Conveniently the compound of this invention and the other active compound are formulated in a pharmaceutical composition. Thus, the present invention also relates to pharmaceutical compositions comprising eprosartan, or its salts, solvates or hydrates, a pharmaceutically acceptable carrier and a second pharmaceutically active compound selected from the group consisting of a diuretic, a calcium channel blocker. , a β-adrenoreceptor blocker, a renin inhibitor and an angiotensin-converting enzyme inhibitor. Examples of compounds that can be included in pharmaceutical compositions in combination with eprosartan, or their salts, solvates or hydrates, are diuretics, particularly a thiazide diuretic, such as chlorhydrothiazide, or a loop diuretic, such as furosemide, calcium channel blockers , particularly dihydropyridine antagonists, such as nifedipine, β-adrenoreceptor blockers, such as propranolol, renin inhibitors, such as enalquinen, and angiotensin-converting enzyme inhibitors, such as captopril or enalapril. Unacceptable toxic pharmacological effects are not expected when eprosartan, or its salts, solvates or hydrates are administered in accordance with the present invention. The eprosartan, or its salts, solvates or hydrates are useful for treating diseases in which blockade of the angiotensin II receptor would be beneficial. Preferably, this compound is used alone or in combination with said second pharmaceutically active compounds in the treatment of hypertension, congestive heart failure and renal insufficiency. In addition, eprosartan, or its salts, solvates or hydrates, has value in the treatment of regression due to left ventricular hypertrophy, diabetic nephropathy, diabetic retinopathy, mascular degeneration, hemorrhagic attack, primary and secondary prevention of infarction, prevention of atheromas progression and in the regression of atheromas, the prevention of restinosis after angioplasty or bypass surgery, to improve cognitive function, angina, glaucoma, and CNS disorders, such as anxiety. The following examples are illustrative of the present invention. These examples are not designed to limit the scope of this invention defined above and as claimed below.

Examples of suspensions in nanoparticles Suspensions were prepared (refer to Table 1 for details of the formulation) by dispersing hydroxypropylmethylcellulose (HPMC) in purified water, using a suitable mixer and stored overnight to hydrate. The drug substance was dispersed using a homogenizer and mixing continuously until no agglomerates of drug remained. The Premier ball mill was adjusted with 0.6-0.8 mm zirconium oxide spheres filling approximately 80% of the milling chamber. The sphere mill was operated according to the manufacturer's instructions in the settings listed in Table 1. After spraying, the particle size distribution of the suspensions of formulas 1-3 was measured using the laser diffraction unit Malvern. The sample was properly diluted, and the particle configurator was operated according to the manufacturer's instructions in the settings listed in Table 1. The results are reported in Table 1 as D (0.1), D (0.5) and D ( 0.9). D (0.1) represents the size (such as average diameter in number), below which 10% of the particles are found, D (0.5) is the size below which 50% of the particles are located, also known as the mean . D (0.9) is the measurement below which 90% of the particles are found.

Examples of biologically improved oral solid formulations The spray suspension was spray-dried using a laboratory scale Yamato GA-32 spray dryer. The spray dryer was operated according to the manufacturer's instructions in the settings listed in Table 1. In this apparatus, the sprayed aqueous suspension was fed by a peristaltic pump into the drying chamber as an atomized spray. The resulting spray-dried powder was further dried [e.g., oven-dried at about 40 ° C] to produce a dry powder composition having adequate flowability / compaction capabilities and therefore, is suitable for filling into hard gelatin capsules (formulas 3-5 in table 1). The spray suspension was spray dried and granulated by spray in a fluid bed granulator. The fluid bed contained the excipients listed in Table 2 (formulas 6 and 7). These granulates were mixed with a disintegrant and a lubricant and compressed to form pharmaceutically elegant tablets.

The spray dried material was further wet granulated using a high shear granulator and compressed to create tablets incorporating widely used excipients (formula 8 in Table 2).

Bio-equivalence studies The test dogs were administered orally in a four-limb study using a dose of 10 mg of eprosartan as zwitterion per kg. The internal granules of the current product (refer to Table 3 for details of the formulation) were used as the control. Bio-equivalence studies were conducted to determine the relative bioavailability of biologically improved oral formulations in healthy volunteers. The design of the study included open, random and crossed. A single oral dose of 200 mg of the following formulations - a commercial tablet, a capsule of the formula 6 and a tablet of the formula 7. Each day of dosing the subjects would receive a single oral dose, with a cleaning of at least 6 days between doses. The doses were administered orally with 200 mL of water, following a normal breakfast. Blood samples were taken at predetermined time points and tested. From the plasma concentration profiles obtained from the clinical studies in both dogs and humans, the UCmax (mg.hr/ml) values [area under the plasma concentration vs. time curve], Cmax (mg.hr/ml) [maximum plasma concentration] and tmax (time in hours to achieve a maximum level in plasma). The results, subjected to adequate statistical tests, showed an increase in blood levels of 2 to 5 times, when dosed with capsules / tablets containing the biologically improved formulations.

TABLE 1 Biologically Improved Formulations for Suspension TABLE 2 Formulations for biologically improved tablet l Water is removed during spray drying.

TABLE 3 Eprosartan commercial product formula Ingredients% p / p Intragranular eprosartan mesylate (400 mg as zwitterion) 61.32 Lactose monohydrate (impalpable) NF 3.59 Microcrystalline cellulose (Avicel PH102) NF 3.59 Pregelatinized starch (Starch 1551) Usp 3.59 Purified water USP 4.36 * Extragranular croscarmellose sodium (Ac-Di-Sol) 4.00 Microcrystalline cellulose (Avicel PH102) NF 19. Magnesium stearate NF 0.75 Tablet core weight (200 mg) 400.00 Film coating Opadry Blue OY-S-20900 ** A control tablet formulation was produced by a high shear Fielder granulator and the average weight diameter of the drug substance (eprosartan mesylate) was about 15 microns. * Purified water is added during the granulation to form the dihydrate of the salt.

** The film coating is applied at a level of approximately 2.5-4% core weight. It is to be understood that the invention is not limited to the embodiments illustrated hereinabove, and that it reserves the right to the illustrated embodiments and all modifications falling within the scope of the following claims.

Claims (12)

NOVELTY OF THE INVENTION CLAIMS

1. - A pharmaceutical composition comprising eprosartan, or a salt, solvate or hydrate thereof, in the form of particles, said composition having a particle size distribution such that the average value of the average volume diameter is in the range of 450 to 700 nm.

2. The composition according to claim 1, further characterized in that eprosartan, or a salt, solvate or hydrate thereof, is eprosartan mesylate.

3. The composition according to claim 1, which is produced by wet spraying eprosartan, or a salt, solvate or hydrate thereof, in the presence of water and pharmaceutically acceptable excipients.

4. The composition according to claim 3, further characterized in that the excipient is hydroxypropylmethylcellulose or mannitol.

5. A process for the preparation of the composition according to claim 1, in which eprosartan, or a salt, solvate or hydrate thereof, in the form of particles, is produced by spraying eprosartan, or a salt, solvate or hydrate thereof, using a sphere mill in the presence of hard spheres of zirconium oxide, water and hydroxypropylmethylcellulose, optionally adding one or more pharmaceutically acceptable excipients, spray drying and filling the resulting powder into capsules.

6.- The use of the composition in accordance with the claim 1 in the manufacture of a medicament for blocking angiotensin II receptors in a subject.

7.- The use of the composition in accordance with the claim 1 in the manufacture of a medicament for treating hypertension in a subject.

8. The use of the composition in accordance with the claim 1 in the manufacture of a medicament for treating congestive heart failure in a subject.

9.- The use of the composition in accordance with the claim 1 in the manufacture of a medicament for treating renal insufficiency in a subject.

10. The use of the composition according to claim 1 in combination with a second pharmaceutically active compound selected from the group consisting of a diuretic, a calcium channel blocker, a β-adrenoreceptor blocker, a renin inhibitor and an angiotensin-converting enzyme inhibitor in the manufacture of a medicament for treating hypertension in a subject.

11. - The use as claimed in claim 10, wherein the second pharmaceutically active compound is a diuretic.

12. The use as claimed in claim 11, wherein the diuretic is chlorhydrothiazide.